GLP-I receptor agonists—including semaglutide and tirzepatide—have been prescribed (on-and-off label) for weight management, including obesity, along with a reduced caloric diet and increased physical activity. Take precaution with, and read all warnings concerning, GLP-1s, as they may cause serious side effects, including a risk of thyroid c-cell tumors and depression. Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome). All claims and benefits on this website are made in reference to studies related to non-compounded forms of Semaglutide and Tirzepatide. Results from compounded medications found on the Remedy Meds platform may vary. We encourage all prospective users of compounded Semaglutide and Tirzepatide to speak with their medical provider about the specific risks and benefits that may come with the use of a compounded medication.